RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Freeline Therapeutics Holdings Stock

Freeline Therapeutics Holdings P/E 2024

Freeline Therapeutics Holdings P/E

-0.05

Ticker

FRLN

ISIN

US35655L1070

WKN

A2QADU

As of Oct 2, 2024, Freeline Therapeutics Holdings's P/E ratio was -0.05, a -78.26% change from the -0.23 P/E ratio recorded in the previous year.

The Freeline Therapeutics Holdings P/E history

Freeline Therapeutics Holdings Aktienanalyse

What does Freeline Therapeutics Holdings do?

Freeline Therapeutics Holdings PLC is a biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company was founded in 2015 and is headquartered in London, United Kingdom. Freeline Therapeutics also has a branch in Munich, Germany. The company focuses on the development and manufacturing of gene therapies using AAV (Adeno-associated viruses) vectors. These vectors serve as delivery vehicles to transport therapeutic genes into cells. Freeline Therapeutics utilizes its expertise in this field to develop innovative gene therapies for patients with rare diseases. Freeline Therapeutics' business model is based on researching, developing, and commercializing gene therapies for rare diseases. The company has several partnerships with other biopharmaceutical companies and academic institutions to advance the development of individual therapeutic approaches. Freeline Therapeutics has three main areas: hemophilia, Krabbe disease, and Fabry disease. In the hemophilia division, Freeline Therapeutics develops gene therapies for patients with hemophilia A and B. The therapy aims to improve the production of the missing clotting factor in the body. Such therapy could reduce or even eliminate the need for repeated infusions required to treat bleeding. In the Krabbe disease division, Freeline Therapeutics is developing a gene therapy for the treatment of Krabbe disease, a rare and life-threatening inherited disorder that affects the central nervous system. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain lipid compounds, thereby slowing down or even stopping the disease. In the Fabry disease division, Freeline Therapeutics is working on developing a gene therapy for the treatment of Fabry disease, a rare disorder that affects the cardiovascular system and other organs. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain fats, thereby slowing down or even stopping the disease. Freeline Therapeutics has several products in development, including FLT180a, FLT190a, and FLT200, all of which represent gene therapies for different rare diseases. FLT180a is a gene therapy being developed for the treatment of hemophilia A. FLT190a is a gene therapy being developed for the treatment of Krabbe disease. FLT200 is a gene therapy being developed for the treatment of Fabry disease. Freeline Therapeutics also has a pipeline of gene therapies currently in the preclinical phase. The company is committed to accelerating the development of gene therapies for rare diseases and improving patients' access to these innovative treatments. Overall, Freeline Therapeutics is an emerging biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company has expertise in AAV vector technology and aims to develop innovative and life-saving therapies for patients with rare diseases. Freeline Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Freeline Therapeutics Holdings's P/E Ratio

The Price to Earnings (P/E) Ratio of Freeline Therapeutics Holdings is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Freeline Therapeutics Holdings's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Freeline Therapeutics Holdings is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Freeline Therapeutics Holdings’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Freeline Therapeutics Holdings stock

What is the price-to-earnings ratio of Freeline Therapeutics Holdings?

The price-earnings ratio of Freeline Therapeutics Holdings is currently -0.05.

How has the price-earnings ratio of Freeline Therapeutics Holdings changed compared to last year?

The price-to-earnings ratio of Freeline Therapeutics Holdings has increased by -78.26% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Freeline Therapeutics Holdings high compared to other companies?

Yes, the price-to-earnings ratio of Freeline Therapeutics Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of Freeline Therapeutics Holdings affect the company?

An increase in the price-earnings ratio of Freeline Therapeutics Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Freeline Therapeutics Holdings affect the company?

A decrease in the price-earnings ratio of Freeline Therapeutics Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Freeline Therapeutics Holdings?

Some factors that influence the price-earnings ratio of Freeline Therapeutics Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Freeline Therapeutics Holdings pay?

Over the past 12 months, Freeline Therapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Freeline Therapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Freeline Therapeutics Holdings?

The current dividend yield of Freeline Therapeutics Holdings is .

When does Freeline Therapeutics Holdings pay dividends?

Freeline Therapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Freeline Therapeutics Holdings?

Freeline Therapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Freeline Therapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Freeline Therapeutics Holdings located?

Freeline Therapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Freeline Therapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Freeline Therapeutics Holdings from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Freeline Therapeutics Holdings pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Freeline Therapeutics Holdings in the year 2023?

In the year 2023, Freeline Therapeutics Holdings distributed 0 USD as dividends.

In which currency does Freeline Therapeutics Holdings pay out the dividend?

The dividends of Freeline Therapeutics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Freeline Therapeutics Holdings

Our stock analysis for Freeline Therapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Freeline Therapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.